IVA vs. MLYS, TRDA, RNAC, HUMA, ARCT, SNDL, KALV, PROK, ABVX, and ORGO
Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Mineralys Therapeutics (MLYS), Entrada Therapeutics (TRDA), Cartesian Therapeutics (RNAC), Humacyte (HUMA), Arcturus Therapeutics (ARCT), SNDL (SNDL), KalVista Pharmaceuticals (KALV), ProKidney (PROK), ABIVAX Société Anonyme (ABVX), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry.
Inventiva vs.
Mineralys Therapeutics (NASDAQ:MLYS) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
Mineralys Therapeutics presently has a consensus price target of $27.00, indicating a potential upside of 182.43%. Inventiva has a consensus price target of $12.60, indicating a potential upside of 343.66%. Given Inventiva's higher possible upside, analysts clearly believe Inventiva is more favorable than Mineralys Therapeutics.
Inventiva's return on equity of 0.00% beat Mineralys Therapeutics' return on equity.
Mineralys Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
In the previous week, Inventiva had 4 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 4 mentions for Inventiva and 0 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.34 beat Inventiva's score of 0.25 indicating that Mineralys Therapeutics is being referred to more favorably in the media.
Inventiva received 6 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 81.48% of users gave Inventiva an outperform vote.
84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Inventiva has higher revenue and earnings than Mineralys Therapeutics.
Summary
Inventiva beats Mineralys Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Inventiva News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inventiva Competitors List
Related Companies and Tools
This page (NASDAQ:IVA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free IVA Stock Alerts